PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…
juliet schaaf19.08.2020
We are proud to announce that BB Pureos Bioventures has become a partner in BaseLaunch Phase II as the first venture capital fund. Anja Harmeier,…
Jérémie Meyer08.06.2020
Congratulations to one of BaseLaunch’s portfolio companies, Polyneuron on their latest milestone: First clinical trial application approval. Wishing you great success with the studies later…
Jérémie Meyer11.05.2020
Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…
Jérémie Meyer05.03.2020
Polyneuron Pharmaceuticals, one of our portfolio companies has successfully raised 22.5 million francs in a round of financing. The Basel-based company will use the proceeds…
Jérémie Meyer04.03.2020
The Basel-based biotech company Alentis Therapeutics AG has successfully concluded a CHF 12.5 million Series A financing co-lead by BioMedPartners and BB Pureos Bioventures and joined by…
Jérémie Meyer03.03.2020
T3 Pharma, a spin-off of the University of Basel and one of our portfolio, has raised over $12 million from Boehringer Ingelheim Venture Fund and…
Jérémie Meyer02.03.2020
Basel-based biopharmaceutical Versameb has raised 6.4 million Swiss francs in a Seed C financing round and will put the funds towards expanding its technology platform.…
Jérémie Meyer01.03.2020
T3 Pharmaceuticals is among the winners of this year’s W.A. de Vigier Award. The spin-off from the University of Basel is developing a targeted cancer…
Jérémie Meyer28.05.2019
